Anticancer Drug Development, a Matter of Money or a Matter of Idea?

Lu Dy Chen Eh

doi:10.4172/2153-0769.1000e134

Abstract

Drug manufacture (highly competitive area) is pillar industry for many developed countries and largest medical expenditures worldwide. Nonetheless, new anticancer drug discovery, development and manufacture have been entering into bottleneck stages. The persistent reducing of successful rates of phase II and phase III anticancer drug evaluations in clinics are grim situations for most anticancer drug developers. Owing to all these undesired factors, anticancer drug developments are highly risky enterprising now. This editorial addresses important factors affecting anticancer drug developments in future.

Highlights

BackgroundsCancer is a malignant disease that is often difficult to be completely controlled or cured [1]
Increasing amount of money must be paid for drug screening, mechanistic studies and developments, it results in skyrocket treatment fee and the whole process of each anticancer licensing (11.8 billion USD) in US and other developed countries [5,6,7]
Several factors can contribute for these drawbacks of present anticancer drug development systems

Summary

Introduction

BackgroundsCancer is a malignant disease that is often difficult to be completely controlled or cured [1]. Despite great advances in recent decades, current cancer therapy has still many limitations, e.g. high costs for conventional therapy and shortage of effective anticancer drugs. Anticancer drug discovery, development and manufacture have been entering into bottleneck stages [2,3,4]. Increasing amount of money must be paid for drug screening, mechanistic studies and developments, it results in skyrocket treatment fee and the whole process of each anticancer licensing (11.8 billion USD) in US and other developed countries [5,6,7].

Results

Conclusion